Tolani F Olonisakin

3PUBLICATIONS
20CO-AUTHORS
Predictive and prognostic markersAllergyBehavioural epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jan 03, 2023
Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.

Marco A Mascarella, Tolani F Olonisakin, Purva Rumde

|Apr 08, 2022
Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin-4 and interleukin-18 production.

Jymirah Morris, Tolani F Olonisakin, John A Moore

|Mar 03, 2022
Fractional Exhaled Nitric Oxide as a Marker of Mucosal Inflammation in Chronic Rhinosinusitis.

Tolani F Olonisakin, John A Moore, Stephanie Barel

Pageof 1